Form 4 for LRMR Larimar Therapeutics, Inc.
Accepted 2025-01-24 00:00:00 ET · period of report 2025-01-22 · accession 0001062993-25-001077 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-24 | 2025-01-22 | LRMR | Celano Michael | CFO | A - Grant | $0.00 | +34.2K | 178.2K | +24% | $0 |
| D | 2025-01-24 | 2025-01-22 | LRMR | Celano Michael | CFO | A - Grant | $0.00 | +205.1K | 205.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-22 | A | A | 34,185 | $0.00 | 178,181 | D | — | — | (F1) Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-01-22 | A | A | 205,111 | $0.00 | 205,111 | D | $3.46 · — to 2035-01-22 | 205,111 Common Stock | (F2) The option vests 25% on January 22, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. |